T cell-tumor cell: A fatal interaction?

Cancer Immunology Immunotherapy

Volumn 47, Issue 2, 1998, Pages 65-71

  Chappell, Dale B ^a   Restifo, Nicholas P ^b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Apoptosis; Cancer; FasL; Immmunotherapy Caspase

Indexed keywords

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL DEATH; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; GENE DELETION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; ONCOGENE C MYC; OPEN READING FRAME; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CELL COMMUNICATION; FAS LIGAND PROTEIN; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; NEOPLASMS; T-LYMPHOCYTES;

EID: 0031693166     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050505     Document Type: Review

References (54)

1. Alexander-Miller MA, Leggall GR, Sarin A, Berzofsky JA (1996) Role of antigen, CDH, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 184:485-492
2. Arai H, Gordon D, Nabel EG, Nabel GJ (1997) Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 94:13862-13867
3. Bump NJ, Hackett M, Hugunin M, Seshagiri S, Brady K, Chen P, Ferenz C, Franklin S, Ghayur T, Li P (1995) Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Science 269:1885-1888
4. Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA, Restifo NP (1996) Costimulation enhances the active immumotherapy effect of recombinant anticancer vaccines. Cancer Res 56:2832-2836
5. Daniel PT, Kroidl A, Cayeux S, Bargou R, Blankenstein T, Dorken B (1997) Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during tarnet cell lysis. J Immunol 59:3808-3815
6. Depraetere V, Golstein P (1997) Fas and other cell death signaling pathways. Semin Immunol 9:93-107
7. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB (1996) Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 335:1643-1649
8. Fisher GH, Rosenberg KJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81, 935-946
9. French LE, Tschopp J (1996) Constitutive Fas ligand expression in several non-lymphoid mouse tissues: implications for immune-protection and cell turnover. Behring Inst Mitt:156-160
10. Friesen C, Herr I, Krammer PH, Debatin KM (1996) Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2:574-577
11. Glass A, Walsh CM, Lynch DH, Clark WR (1996) Regulation of the Fas lytic pathway in cloned CTL. J Immunol 156:3638-3644
12. Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P, Ohgaki H (1997) Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 7:863-869
13. Green DR (1997) A Myc-induced apoptosis pathway surfaces [comment]. Science 278:1246-1247
14. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192
15. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363-1366
16. Hornung F, Zheng L, Lenardo MJ (1997) Maintenance of clonotype specificity in CD95/Apo-1/Fas-mediated apoptosis of mature T lymphocytes. J Immunol 159:3816-3822
17. Houghton JA, Harwood FG, Tillman DM (1997) Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc Natl Acad Sci USA 94:8144-8149
18. Hueber AO, Zornig M, Lyon D, Suda T, Nagata S, Evan GI (1997) Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 278:1305-1309
19. Iezzi G, Karjalainen K, Lanzavecchia A (1998) The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8:89-95
20. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388:190-195
21. Kang SM, Hoffmann A, Le D, Springer ML, Stock PG, Blau HM (1997) Immune response and myoblasts that express Fas ligand. Science 278:1322-1324
22. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S (1997) Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 3:738-743
23. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H (1995) Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182:1777-1783
24. Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS (1997) Mutations in the Fas antigen in patients with multiple myeloma. Blood 90:4266-4270
25. Lenardo MJ (1997) The molecular regulation of lymphocyte apoptosis. Semin Immunol 9:1-5
26. Mandruzzato S, Brasseur F, Andry G, Boon T, Bruggen P van der (1997) A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 186:785-793
27. Matiba B, Mariani SM, Krammer PH (1997) The CD95 system and the death of a lymphocyte. Semin Immunol 9:59-68
28. McFarland HI, Critchfield JM, Racke MK, Mueller JP, Nye SH, Boehme SA, Lenardo MJ (1995) Amelioration of autoimmune reactions by antigen-induced apoptosis of T cells. Adv Exp Med Biol 383:157 66, 157 166
29. Miller DK (1997) The role of the Caspase family of cysteine proteases in apoptosis. Semin Immunol 9:35-49
30. Minn AJ, Velez P, Schendel SL, Liang H, Muchmore SW, Fesik SW, Fill M, Thompson CB (1997) Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature 385:353-357
31. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor ligand system and involves activation of wild-type p53. J Clin Invest 99:403-413
32. Nagata S, Golstein P (1995) The Fas death factor. Science 267:1449-1456
33. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA (1997) Human lung carcinomas express Fas ligand. Cancer Res 57:1007-1012
34. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075-1082
35. Reap EA, Roof K, Maynor K, Borrero M, Booker J, Cohen PL (1997) Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions. Proc Natl Acad Sci USA 94:5750-5755
36. Reed JC (1997) Double identity for proteins of the Bcl-2 family. Nature 387:773-776
37. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA (1996) Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100-108
38. Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175-182
39. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, Van Meir EG, Tribolet N de, Tschopp J, Dietrich PY (1997) Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 99:1173-1178
40. Sata M, Walsh K (1998) TNF-alpha regulation of fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 4:415-420
41. Seino K, Kayagaki N, Okumura K, Yagita H (1997) Antitumor effect of locally produced CD95 ligand. Nat Med 3:165-170
42. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H (1997) Expression of Fas ligand in liver metastases of human colonie adenocarcinomas. Proc Natl Acad Sci USA 94:6420-6425
43. Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y, Fleisher TA, Lim MS, Jaffe ES, Puck JM, Lenardo MJ, Straus SE (1997) Clincial, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 89:1341-1348
44. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells a mechanism of immune evasion?. Nat Med 2:1361-1366
45. Tamura T, Aoyama N, Saya H, Haga H, Futami S, Miyamoto M, Koh T, Ariyasu T, Tachi M, Kasuga M (1995) Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene 11:1939-1946
46. Tanaka M, Itai T, Adachi M, Nagata S (1998) Downregulation of Fas ligand by shedding. Nat Med 4:31-36
47. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schroter M, Scaffidi C, Krummer PH, Peter ME, Tschopp J (1997) Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517-521
48. Vito P, Lacana E, D'Adamio E (1996) Interfering with apoptosis: Ca(2+)-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science 271:521-525
49. von Reyher U, Strater J, Kittstein W, Gschwendt M, Krammer PH, Moller P (1998) Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res 58:526-534
50. Wang RF, Rosenberg SA (1996) Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. J Leukoc Biol 60:296-309
51. Wojtowicz-Praga S (1997) Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 20:165-177
52. Young MR, Wright MA, Matthews JP, Malik I, Prechel M (1996) Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. J Immunol 156:1916-1922
53. Zornig M, Grzeschiczek A, Kowalski MB, Hartmann KU, Moroy T (1995) Loss of Fas Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene 10:2397-2401
54. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X (1997) Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90:405-413